OXM issynthesized through the processing of pre-pro-glucagon to pro-glucagon, which isthen processed by PCSK1 (Subtilisin/kexin type 1 proprotein convertase), culminatingin the release of mature OXM(3).This hormone binds to the glucagon-like peptide 1 (GLP-1) receptor and the glucagonreceptor(4), leading to theinhibition of glucagon secretion, a reduction in caloric intake, an increase inenergy expenditure(5), and weightloss in obese patients (6).Abnormal secretion of incretins, including OXM, has been observed in individualswith type 2 diabetes mellitus (7). The gene discussed is GCG; the disease is type 2 diabetes mellitus.